TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA cleared Encora Therapeutics’ wrist-worn device to help adults with essential tremor, nearly nine years after an MIT student team first demonstrated a prototype. The device uses vibration, and a company-reported clinical trial found that 78% of patients reported benefits after 90 days of home use; the source does not provide further trial details.
Encora Therapeutics’ wrist-worn tremor device received U.S. Food and Drug Administration clearance in February to help adults with essential tremor, the company’s development journey having begun as an MIT class project in 2017. The clearance moves the vibration-based device from student prototype to a regulated treatment option; the source does not specify its availability or the exact terms of the clearance.
The device grew out of MIT’s 2.009 product engineering class, where a student team developed a wristband intended to use mechanical vibration to affect movement-control signals. During a 2017 demonstration at MIT’s Kresge Auditorium, a man identified as Michael, who had Parkinson’s disease, put on the prototype and drew a spiral with greater precision than before, according to MIT News. That demonstration showed an individual response, not a clinical finding.
MIT News reports that the founding team continued developing the technology, formed Encora Therapeutics in 2020 and completed multiple hardware iterations and clinical work. A trial involving people with Parkinson’s disease began in 2022 in collaboration with Mass General Brigham. The team later focused on essential tremor, which company co-founder Daniel Carballo said represented a greater unmet need.
In one trial, 78% of patients reported benefits after 90 days of using the device at home, according to the source report. The supplied material does not identify the trial’s participant count, study design, outcome measure or comparison group. That percentage is a patient-reported result over the stated 90-day period, not a claim that the device reduced tremors by 78%.
A New Option for Essential Tremor
Essential tremor can cause shaking, often in the hands, and can interfere with everyday tasks. FDA clearance gives adults with the condition access to a device-based approach that does not rely on the medication or surgical procedures mentioned in the source as other ways of addressing tremor. The available material does not establish how the device compares with those options or which patients are most likely to benefit.
The news also marks a practical milestone for the student project: it has passed beyond a classroom demonstration into a product cleared for a defined adult population. That matters to patients and clinicians considering available approaches, while the reported trial result and one person’s demonstration should not be taken as proof that every user will experience the same effect.
As an affiliate, we earn on qualifying purchases.
From MIT Prototype to Clearance
The original 2017 class project was aimed at helping people with Parkinson’s disease. After the live demonstration attracted requests from people seeking a device for relatives, some members of the team used MIT entrepreneurship programs to continue the work. The founders formed Encora in 2020, but moving from a foam-core prototype to a wearable product required further engineering and clinical testing, according to MIT News.
The team’s early clinical work included a 2022 trial with 20 Parkinson’s patients, conducted with Mass General Brigham. During development, the company shifted its focus to essential tremor. Carballo told MIT News that there were more drugs being developed for Parkinson’s than for essential tremor, which he described as having a greater unmet need. The FDA clearance reported in February 2026 applies to helping adults with essential tremor; the supplied report does not say that the cleared use includes Parkinson’s disease.
““It’s been a long and difficult — very difficult — journey, but also very rewarding, especially when we get feedback from patients.””
— Daniel Carballo, Encora co-founder and vice president of strategy, speaking to MIT News
essential tremor vibration therapy device
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Trial Details and Access Still Unclear
The source report does not give the date of the FDA decision beyond February 2026, the clearance documentation, device name, instructions for use, price or launch schedule. It also does not describe the 90-day trial in enough detail to assess its design, participant number, reported benefit measure or potential limitations. Those details are needed to understand how the result should be interpreted.
It is also unclear how large or durable the benefit may be across different users, what side effects or limitations were reported, and how the device compares with existing approaches. The FDA clearance is described as covering help for adults with essential tremor; the source does not say that the device is cleared to treat Parkinson’s disease or eliminate tremors.
As an affiliate, we earn on qualifying purchases.
Availability and Further Evidence
The next practical questions concern when adults with essential tremor can obtain the device, how it will be prescribed or supplied, and what costs may apply. The supplied report gives no timetable for availability and no information about insurance coverage. Clinicians and potential users will also need product instructions and fuller clinical evidence to understand who may be suited to use it.
Further published trial information could clarify the 78% patient-reported benefit figure, including how many people took part, how benefit was measured and whether it persisted beyond 90 days. Until those details are available, the confirmed development is the FDA clearance for helping adults with essential tremor, alongside a reported but incompletely described trial outcome.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA clear?
The source reports that in February 2026 the FDA cleared Encora Therapeutics’ wrist-worn device to help adults with essential tremor. It does not provide the device name or detailed clearance terms.
How does the device work?
The device uses mechanical vibration delivered through a wristband. The student team developed it to send sensory signals that may affect movement control. The supplied report does not give detailed operating instructions or explain the mechanism in full.
Does the clearance cover Parkinson’s disease?
The reported FDA clearance is for helping adults with essential tremor. Although the original prototype was demonstrated by a person with Parkinson’s disease and the team conducted Parkinson’s research, the source does not say the cleared use includes Parkinson’s disease.
What does the 78% figure mean?
In one trial, 78% of patients reported benefits after 90 days of home use, according to MIT News. The report does not provide the number of participants or enough study detail to interpret the result beyond that description.
When will the device be available?
The source material does not state when the device will go on sale, how much it will cost or whether insurance will cover it. Those access details remain unclear.
Source: hn
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
